Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Equinix Inc (EQIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Equinix Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Equinix Inc trades at $1,054 (market cap $103.67B). The key difference: Equinix Inc is far larger — about 2.6× Alnylam Pharmaceuticals, Inc.'s market cap, and Equinix Inc pays a 1.87% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | EQIX | |
|---|---|---|
Market Cap | $39.89B | $103.67B |
Sector | Health | Real Estate |
52-Week High | $491.22 | $1.12K |
52-Week Low | $278.09 | $726.09 |
Enterprise Value | $38.15B | $123.96B |
Dividend Yield | — | 1.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Equinix (EQIX) trades at $1,051.21, up 1.58% with a bearish technical signal despite strong analyst support. The data center REIT shows solid revenue growth to $9.22B in 2025 and expanding profit margins of 15.07%, though valuation metrics remain elevated with a P/E of 72.7. Recent partnerships with Cisco and NVIDIA position EQIX to capitalize on AI infrastructure demand, while negative cash flow trends and rising debt-to-asset ratios present financial concerns.
The outlook balances AI-driven growth potential against valuation and leverage risks. With 74.5% analyst buy ratings and a $1,120 consensus price target suggesting 6.5% upside, institutional sentiment remains positive. However, investors face execution risks in capital-intensive expansion and sensitivity to interest rate changes given the REIT structure and substantial debt load.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →
